COVID-19 preclinical drug development database

Targeting intracellular vesicular trafficking using a novel V-ATPase inhibitor to ameliorate pathogenicity of SARS-CoV-2 and related viral pathogens

King's College London

Added 08/07/2020 | Updated 04/10/2021

Back

Project Details

Type of project

  • Tier 2: testing existing molecules
  • Tier 3: discovering and categorising new molecules
  • Target identification or validation

Therapeutic target

  • Preventing infection (prophylaxis or preventing cell entry)
  • Preventing virus replication in early disease
  • Preventing cytokine release syndrome (immunomodulation or suppression)

Type of supporting technology

Phase of project

  • Lead optimisation and activity validation
  • proof of concept study to validate target of new compound

Modality (if can be disclosed)*

  • Small molecule

Molecular/cellular target (if known or can be disclosed)*

  • V-ATPase

Partner institutions/organisations

  • King's College London

Key contact

Name: Agamemnon E Grigoriadis

Email Address: [email protected]

Phone Number: 020-7188-1807

Key Collaborators:
Prof Agamemnon Grigoriadis Prof Paul Long Prof Michael Malim

Anticipated timeframe of future outputs

3-6 months

Further Details

Abstract or additional information (if available)*

Published outputs (if available)*

Relevant weblinks

Similar Projects

Project Name
Lead institution
Isolation of SARS-CoV-2 broadly neutralising antibodies
King's College London
Link
Mesenchymal stromal cells for the early treatment of cytokine release syndrome
King's College London
Link
High throughput screening of approved drugs to search for inhibitors of SARS-CoV-2 Spike protein-induced cell-cell fusion
King's College London
Link
Identification of New Therapeutic Combinations for Clinical Trial against COVID-19 Through Repurposing of Drugs with Known Safety Profile.
King's College London
Link